Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 15/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 15/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 15/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 15/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 15/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 15/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209167 | 1.00 | BTK (0.37) | BTKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2204678 | 1.00 | BTK (0.37) | BTKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2207417 | 1.00 | BTK (0.37) | BTKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2204684 | 1.00 | BTK (0.37) | BTKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2210618 | 0.91 | ROCK2 (0.38) | BTKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2234541 | 0.85 | ROCK2 (0.34) | ROCK2 | |
| SCHEMBL2235695 | 0.85 | ROCK2 (0.34) | ROCK2 | |
| SCHEMBL2241638 | 0.85 | ROCK2 (0.34) | ROCK2 | |
| SCHEMBL2234547 | 0.85 | ROCK2 (0.34) | ROCK2 | |
| SCHEMBL2240560 | 0.85 | ROCK2 (0.34) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029579-B1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2029579-B1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2014-12-31 | — | — | EP | disclosed |
| US-7981918-B2 | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981918-B2 | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981918-B2 | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090111800-A1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-30 | — | — | US | disclosed |
| US-20090111800-A1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-30 | — | — | US | disclosed |
| US-20090111800-A1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-30 | — | — | US | disclosed |
| EP-2029579-A2 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007124254-A2 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124254-A2 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111800-A1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD17B1 | BTK 2136/4885PSEN1 728/4885PSEN2 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.